NEW YORK (GenomeWeb) – Clearbridge Health subsidiary SAM Laboratory will be the exclusive provider of NanoString Technologies’ Prosigna breast cancer prognostic gene signature assay to patients in Singapore, Malaysia, Indonesia, and the Philippines, Clearbridge said yesterday.
Under the terms of the agreement, Clearbridge will also distribute the assay on a non-exclusive basis throughout the rest of Asia, pending applicable local regulatory approvals.
“We believe that providing Prosigna, the [US Food and Drug Administration]-approved breast cancer recurrence risk test, will enable clinicians to better inform their patients on treatment options,” Clearbridge Health CEO Jeremy Yee said in a statement. “Breast cancer is a growing disease in Asia, and CBH is focused on addressing this clinical need by delivering molecular diagnostics to improve disease management and patient outcomes.”
Financial terms of the agreement were not disclosed.